Hopantenic Acid Research Articles

The effect of hopanthenic acid on the development of cognitive disorders in patients with a mine blast injury

Background. In the conditions of hostilities in Ukraine, the number of victims ofmine- explosive injuries among both the military and the civilian population is increasing. These injuries lead to serious damage to the organs and body systems, as well as to the development of various psychological disorders, such as cognitive disorders. The purpose of this paper is to study and correct cognitive disorders in patients with brain concussion due to a mine-explosive injury, using the calcium salt of hopantenic acid. Materials and Methods. For this, the patients underwent the Montreal scale of cognitive function assessment (MoCA), the short mental status assessment scale (MMSE), word encryption tests, and word recall tests. Results. The study was conducted three times, immediately after the injury, and 14 and 21 days later. In the course of the study, it was found that therapy with the calcium salt of hopantenic acid significantly improved neuropsychological indicators (increase in the total MMSE score) and reduced the patient’s cognitive deficit, improved concentration and short-term memory. Conclusions. Thus, the hopantenic acid effectively reduces cognitive impairment in patients with brain concussion due to a mine-explosive injury and is recommended for the treatment of this group of patients.

PATHOPHYSIOLOGICAL ASPECTS OF HABILITATION AND REHABILITATION OF CHILDREN FROM CHILDREN’S HOMES WITH NEURODEVELOPMENTAL DELAY OF PSYCHOSOCIAL GENESIS

Background. Psycho-emotional stress in institutionalized children leads to significant tension in regulatory systems. Justification for using a complex of habilitation and rehabilitation measures aimed at reducing the stress factor and cre-ating conditions for “catch-up” development is an urgent problem. The aim of the study. To create and to test the effectiveness of a complex of habilitation and rehabilitation measures aimed at reducing deprivation pressure and environmental stress. Material and methods. The study included 114 children from children’s homes of Donetsk and Makeevka and 44 chil-dren from families aged 3 to 7 years. The complex of habilitation and rehabilitation measures included optimization of the daily routine, conditioning exercises, music, toy and fairy tale therapy, sessions of individual play and play in small groups of 2–3 people in a separate playroom, phototherapy with bright solar spectrum lamps, enriched sensory envi-ronment, increased physical activity, differentiated drug support with L-carnitine, glycine, hopantenic acid, magnesium and pyridoxine complex. Neuropsychic development was studied using the Denver Screening Test and the Formalized Card for the Study of Psychoneurological Functions according to I.A. Skvortsov and N.A. Ermolenko. The functions of regulatory systems were assessed by the level of cortisol and melatonin in saliva, and brain-derived neurotrophic factor in blood serum. Conclusion. A comparison of the results of assessing the parameters of neuropsychic development confirmed the effec-tiveness of the proposed complex of habilitation and rehabilitation measures. Restoration of the function of regulatory systems was confirmed by normalization of the rhythms of cortisol and melatonin synthesis, as well as by a significant (3-fold) increase in the content of brain-derived neurotrophic factor in the blood serum in children of the main group.

Cognitive function restoration in rats with chronic brain ischemia using Semax and hopantenic acid comprehensive administration

The relevance and importance of treating patients with ischemic brain lesions are indisputable. Chronic ischemic processes in the brain occur much more frequently than acute cerebral circulation disorders, leading to prolonged disability and being the main contributors to a significant number of strokes. Cognitive dysfunctions prevail in the dynamics of the post-ischemic period and are often the primary determinants of the severity of residual organic and subsequent functional impairments of the brain. The aim of the study is to investigate the effectiveness of separate and combined administration of Semax and hopantenic acid in the pharmacological correction of cognitive disorders in rats with experimental chronic brain ischemia. It has been established that rats with chronic brain ischemia exhibit cognitive impairments from the 1st day, manifested in worsened learning processes, short-term and long-term memory functioning in the context of conditioned active avoidance and conditioned feeding reflexes. It has been shown that separate and combined application of Semax and hopantenic acid contributes to the restoration of the learning process and improvement of mnestic functions in rats with chronic brain ischemia. The most pronounced nootropic effect in rats with chronic brain ischemia was registered under the conditions of combined administration of Semax and hopantenic acid, starting from the 3rd day of the study. Subsequently, in terms of anti-ischemic efficacy, the effect of Semax follows, which was realized starting from the 3rd day of the study. The least pronounced neuroprotective effect belongs to hopantenic acid, starting from the 7th day of the study. The author considers the obtained data as experimental groundwork for the feasibility of clinically testing the nootropic effects of the combined administration of Semax and hopantenic acid in cases of chronic brain ischemia. The comprehensive pharmacological correction of cognitive disorders in chronic brain ischemia is pathogenetically justified and aimed at activating sanogenetic mechanisms.

Muscle activity and emotional behavior changes in rats with chronic brain ischemia via comprehensive pathogenetic correction

Cerebrovascular pathology has evolved from a medical concern to a social issue, with the efficacy of secondary neuroprotection remaining a pertinent question. While some investigations have been conducted to elucidate the effectiveness of a comprehensively grounded pharmacological correction scheme under conditions of experimentaly induced chronic brain ischemia, further refinement is necessary to understand the behavioral effects of animals, dosages, routes of administration of pharmacological agents, and analysis of obtained data. The aim of this study was to assess the effectiveness of applying Semax and hopantenic acid in the comprehensive treatment of motor disorders and established neurological impairments in rats with experimentally induced chronic brain ischemia. We determined that rats with chronic brain ischemia exhibit muscular dysfunctions and experience pronounced disturbances in emotional behavior from the first day. It has been demonstrated that the separate and combined application of Semax and hopantenic acid contributes to the restoration of muscle activity, normalization of coordination, and emotional behavior in rats with chronic brain ischemia. The most significant neuroprotective effect in rats with chronic brain ischemia was observed with the combined administration of Semax and hopantenic acid, starting from the 3rd day of the trial. The subsequent in the series of anti-ischemic effectiveness is the impact of Semax from the 3rd day of the experiment. The least pronounced neuroprotective effect was exhibited by hopantenic acid, starting from the 5th day of the experiment. We consider these findings to be an experimental foundation supporting the feasibility of clinically testing the effects of combined Semax and hopantenic acid administration, capable of restoring functional disorders caused by chronic brain ischemia. In conclusion, the observed effectiveness of the developed pathogenetically justified complex for the correction of post-ischemic muscle dysfunction and disorders indicates the development of an anti-ischemic effect, as well as the fundamental possibility of improving the treatment for patients with chronic brain ischemia through clinical intranasal administration of Semax, either alone or in combination with hopantenic acid. However, for a more comprehensive understanding of the temporal and dose-dependent effects of this complex pathogenetic correction scheme on other disorders and dysfunctions related to chronic brain ischemia and to formulate final conclusions, it is essential to conduct separate series of experimental studies.

Management of Children with Speech Disorders via Transcranial Magnetic Stimulation: Non-Randomized Controlled Study

Background. Speech development impairment is urgent and common problem in pediatric neurology. Transcranial magnetic stimulation (TMS) is one of the promising treatment variants for children with speech disorders. Objective. The aim of the study is to evaluate efficacy and safety of the developed approaches to TMS usage in the management of children with speech disorders. Methods. It was non-randomized controlled study. It included 46 children with speech disorders aged from 3 to 6.5 years. All children were divided into two groups comparable by gender and age: 26 children of the treatment group received TMS course, 20 children of the control group received treatment with hopantenic acid. All patients with speech disorders underwent psychological and pedagogical evaluation of speech and cognitive development, electroencephalography (EEG) before and after treatment. Moreover, comparative analysis of TMS and nootropic therapy efficacy was carried out. Specialized examination of speech and cognitive development was also performed via E.A. Strebeleva method for psychological and pedagogical diagnosis of children development. Furthermore, we carried out side reactions / adverse events registration according to patients and/or their parents complaints confirmed by physical examination, patient’s behavior observation, data from specially developed questionnaire for assessing child’s behavior and well-being (filled up by parents). Finally, we evaluated brain bioelectric activity recorded by EEG. Results. The study results have shown that it is possible to achieve significant positive dynamics in cognitive and speech development in preschool children with speech disorders in both groups (TMS course and medical treatment). But hereby, TMS treatment has demonstrated significantly higher positive dynamics in two out of the three evaluated parameters. There were no cases of adverse events in TMS group leading to early course discontinuation. Conclusion. TMS is non-invasive and safe method for treatment of children with speech disorders. This study has demonstrated the efficacy of the method in the field of personalized management of children with impaired speech and cognitive development.

Aduvant therapy of depression with hopantenic acid

Adequate SSRI monotherapy does not produce a sufficient clinical effect in some patients, and about 30% of patients do not respond to therapy at all. Favorable experience of combined prescription of SSRIs with various nootropic (neuroprotective) agents has been described in the literature.The aim of the study was to investigate the efficacy and tolerability of hopantenic acid as an adjuvant therapy for depression. We obtained significant data that inclusion of hopantenic acid at a dose of 2000 mg per day in a 12-week complex antidepressant therapy with paroxetine (20 mg per day) statistically significantly reduces the severity of depression symptoms. The drug's effect is achieved by improving patients' cognitive functions, reducing anxiety symptoms and side effects of SSRIs. Improved efficacy and tolerability of antidepressant therapy with hopantenic acid in the long term will allow to achieve more significant improvement in the quality of life of patients.

Biopharmaceutical and pharmacokinetic aspects of hopantenic acid in pediatric pharmacotherapy

The development of efficient, high-quality, harmless and affordable pharmaceutical forms for drug treatment in pediatrics is a current task of contemporary pharmacy. Currently, psychiatrists and neurologists from various curative-prophylactic institutions prescribe for children and adolescents nootropic preparations in the form of tablets, powders and syrups, in various neurological diseases, the share of which, according to national and international statistics, is constantly increasing. Currently, the prescription of hopanthenic acid is gaining popularity, thanks to its neuroprotective, neurotrophic, neurometabolic, antidepressant, anxiolytic and analgesic effects. The presented paper has as starting point the analysis of the structural-molecular properties of hopanthenic acid, exposed by biopharmaceutical study, pharmacokinetic parameters and strategies for optimizing pharmaceutical formulations with gastric release.

Hopantomide in pediatric neurological practice: outlooks

Hopantomide® is a drug containing calcium salt of hopantenic acid. The drug is registered and produced in Russia (Usolye-Siberian Chemical Pharmaceutical Factory) with the use of own raw materials and goes through a full production cycle, which guarantees quality control at every stage. Hopantomide belongs to nootropics and has neurometabolic, neuroprotective, and neurotrophic properties, as well as anticonvulsant action. According to the package insert and results of the studies evaluating the efficacy of hopantenic acid, Hopantomide has a number of positive therapeutic effects. It increases brain resistance to hypoxia and toxic substances, stimulates anabolic processes in neurons, improves mental and physical performance, combines moderate sedative action with mild stimulating effect, reduces motor excitability with simultaneous regulation of behavior, improves the metabolism of gamma-aminobutyric acid and normalizes its level in individuals with chronic alcohol intoxication and after alcohol withdrawal, has anxiolytic and thymoleptic properties, inhibits the abnormal bladder reflex and detrusor tone. This ensures high efficacy of Hopantomide in the treatment of various nervous diseases in different age groups. In our opinion, the combination of various positive effects of just one drug can significantly reduce the pharmacological burden. In this review, we discuss well-known and potential mechanisms of action, indications for its use with a focus on Hopantomide benefits in pediatric neurological practice, and studies evaluating the efficacy of hopantenic acid in clinical practice. Particular attention is paid to the possibilities of its use in children, including those with attention deficit hyperactivity disorder and developmental delay, as well as the part of combination therapy for epilepsy together with antiepileptic drugs.Drugs containing hopantenic acid are well tolerated by patients, including children who receive it for a long time.

Principles of masking organoleptic properties of bitter tasting medicines

Patient compliance of drug therapy is the key factor in achieving the pharmaceutical effect. Taste masking is particularly important in pediatrics and geriatrics because the unpleasant taste negatively affects drug uptake. Patient compliance can be improved through balanced organoleptic properties of medicines. It is particularly important to choose optimal correction method for medicines with high concentration of the active substance. Hopantenic acid has been chosen as a model drug due to its bitter taste. Taste masking technologies for creating a new dosage form with optimal organoleptic properties are proposed in the article. The objective is to achieve an experimentally justified choice of technological approach to masking bitter taste of a substance and to create a new dosage form on its basis. Materials and methods. Alternative technologies were considered to solve this problem: granulation, creation of complexes with ion-exchange resins, introduction of a gel composition and taste-masking using sweeteners. Organoleptic properties in dry compositions (pure substance of hopantenic acid, granulate and resinate based on it), and also after preparation of liquid dosage forms and incorporation them into gel, were evaluated by A. I. Tentsova method. Choice of sweetener and its concentration to achieve an optimally balanced taste took place at the final stage. Hopantenic acid was chosen as a model substance. Hopantenic acid is a nootropic drug stimulating cognitive functions, nervous system, enhancing intellectual functioning, decreasing nervous system activity, with anticonvulsant action. The main therapeutic indications are mental retardation, dementia, epilepsy. Results and discussion. The study has shown that optimal technology for masking unpleasant taste of hopantenic acid is its introduction into a gel composition, and a promising dosage form is an oral gel. Compri-Zucker G sweetener (Südzucker АG, Germany) in concentration of 5 % has been chosen to create pleasant taste due to its highest taste rating. Conclusion. It has been determined as a result of the study that oral gel with active drug concentration of 5 % and sweetener concentration of 5 % has optimal organoleptic properties. Thus, this combination of active and additional substances can be considered the most perspective for developing a new dosage form of a medicine.

Tics and Tourette's syndrome in children

The article represents a review of modern literature on tics and Tourette's syndrome in paediatric population and describes recent advances in neurogenetics, neuroanatomy and neurotransmitter heterogeneity of the disease pathogenesis. The analysis of the literature supports the plausibility of transformation of tics and Tourette's syndrome from psychiatric disorders into neurological disorders (according to ICD-11) based on recent data on neurophysiology and functional neuroanatomy. Neuroanatomy of motor behaviour is described as the most complex self-regulating neural network of thalamo-cortical loop, basal ganglia in combination with the limbic system, insular and cingulate cortex with involvement of hippocampus, subthalamic region and cerebellum. The evaluation of pharmaceutical treatment options has been carried out, including a review of successful local experience in treating tics in paediatric patients with hopantenic acid, topiramate and neuropeptides of cortexin.

CLINICAL AND NEUROLOGICAL MANIFESTATIONS OF DRUG-RESISTANT EPILEPSY AND OPTIMIZATION OF PATIENT TREATMENT

Aim – to study the clinical and neurological manifestations in patients with drug-resistant epilepsy and optimize the therapy. Materials and methods. Fifty patients with drug-resistant epilepsy were examined. Of these, 28 were females and 22 were males; their average age was 32.6±11.4 years. All patients had true pharmacoresistant epilepsy, i. e., the seizures occurred on the background of adequate polytherapy with anticonvulsants; the use of anticonvulsants had no effect on the course of the disease. All patients underwent clinical and neurological examination. The patients were blindly divided into two therapeutic groups: the main group consisted of 25 patients who were prescribed with the combined therapy, which included a biologically active polypeptide at a dose of 10 mg/day for 20 days with a subsequent transition to hopantenic acid (500 mg twice a day for 2 months). The second group did not receive these drugs. For the anticonvulsant therapy, both groups received the combinations of valproic acid (30 mg/kg at two daily doses) and carbamazepine (5 mg/kg at three daily doses). The significance of differences was determined by the paired and unpaired Student’s t-test. The differences were considered statistically significant at p <0.05. Results. The data on the occurrence of subjective and focal neurological symptoms indicated the prevalence of complaints characteristic of general cerebral symptoms in the form of headaches, dizziness, as well as subjective symptoms of cerebral asthenia. In addition, some patients complained of short-term memory impairments. In most cases, drug-resistant epilepsy developed on the background of organic brain damage. In 87.2±6.9% of cases, we encountered a Chvostek sign indicating an increased excitability of the nervous system. Both groups of patients showed positive yet different clinical dynamics: the number of seizures decreased in 40% of patients taking the polypeptide regulator and hopantenic acid, and in 28% of patients in the comparison group (p<0.05). Conclusion. In order to optimize the anticonvulsant therapy, it is recommended to prescribe a combination of valproate and carbamazepine; to increase the efficacy of the combined therapy it is recommended to add the polypeptide regulator and hopantenic acid.

Pharmacotherapy of psychomotor developmental delay in 6-12 months preterm infants with hypoxic-ischemic encephalopathy (the double-blind comparative multicenter placebo-controlled study)

To evaluate the efficacy and safety of hopantenic acid (Pantogam) in the complex treatment of prematurely born infants, aged 6-12 months, with psychomotor developmental delay due to hypoxic-ischemic encephalopathy. Eighty-seven patients were randomized into two groups: 44 received standardized treatment and pantogam for two months, 43 standardized treatment and placebo. Pantogam (syrup 100 mg/ml) or placebo were prescribed orally 15-30 minutes after feeding, twice a day, in a daily dosage of 30-50 mg/kg body weight. The assessment of psychomotor development from birth to two years was performed with the Griffiths Mental Development Scales (GMDS-ER) twice (before and after completion of therapy). The response to two month therapy determined as the reduction of developmental delay for more than 6% of the initial GMDS-ER general quotient (GQ) score was significantly better in the group I after pantogam treatment (63.6% of patients) compared to group II (36.4%, p=0.021). Group I demonstrated the significant decrease of the developmental delay in two domains ('Personal-Social' and 'Performance') and a trend to overcome the delay in three other domains: 'Locomotor', 'Hearing and Speech', 'Eye and Hand Coordination'. The improvement after pantogam treatment was more obvious in the subgroup of infants born late preterm (gestational age 34-36 weeks) compared to infants born moderate preterm (gestational age 32-33 weeks). The favorable safety profile of pantogam was confirmed, comparable to that of placebo. Pantogam is efficient and safe medication in the complex treatment of psychomotor developmental delay in preterm infants, aged 6-12 months.

Pharmacotherapy of Attention Deficit Hyperactivity Disorder in Children: Results of a Multicenter, Double-Blind, Placebo-Controlled Trial of Hopantenic Acid

Objectives. To assess the efficacy and safety of hopantenic acid (Pantogam) compared with placebo in the treatment of ADHD for four months in children aged 6–12 years during a prospective, multicenter, comparative, double-blind, placebo-controlled, parallel-group trial. Materials and methods. The study included 100 patients constituting the safety population (50 in the Pantogam group and 50 in the placebo group). A total of 89 patients completing the study in compliance with the protocol entered the efficacy evaluation population: 45 in the Pantogam group (group 1) and 44 in the placebo group (group 2). Pantogam was given as tablets containing 250 mg at the pediatric therapeutic dose of 30 mg/kg, divided into two split doses, for four months. Assessment of patients’ statements at follow-up addressed the total points scores on the DSM-IV ADHD, the CGI-S Clinical Global Impression scale, the WFIRS-P functional impairments scale, and the results of a correction test (the Toulouse–Pieron test). Results and conclusions. The efficacy of Pantogam in ADHD in children aged 6–12 years as compared with placebo showed a marked tendency to an increase in the proportion of patients with improvements (decreases in total points scores on the DSM-IV ADHD scale by more than 25%) by the ends of the third and fourth months of treatment: treatment responses were achieved in 66.7% and 68.9%, respectively, compared with 52.3% and 61.4% in the placebo group. Pantogam therapy also produced a decrease in disease severity from the placebo level on the CGI-S scale. At four months of Pantogam treatment, there were decreases in the severity of functional impairments on sections 4 and 6 of the WFIRES-P “Family,” “School and learning,” “Child’s self-concept,” and “Risky activities” scales. Pantogam also improved the maintenance of attention in children with ADHD, as measured using the Toulouse–Pieron test (quality and rate of performance) as compared with placebo. Treatment with Pantogam at a mean daily dose of 30 mg/kg for four months demonstrated a favorable safety profile, no different from that of placebo.

A New Hopantenic Acid Derivative from the Rhizomes of Heterosmilax japonica

A new hopantenic acid derivative, (R)-methyl-4-(2,4-dihydroxy-3,3-dimethylbutanamido)butanoate (1), was isolated from the rhizomes of Heterosmilax japonica Kunth, together with three known compounds, (3S)-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid (2), daucosterol (3), and ethyl-β-D-xylobioside (4). The structure of 1 was determined by extensive spectroscopic analyses, including 1D and 2D NMR and HR-ESI-MS. Compounds 2 and 4 are new for the genus Heterosmilax.

Перспективы применения гопантеновой кислоты в психиатрической практике

Перспективы применения гопантеновой кислоты в психиатрической практике

Исследование эффективности применения гопантеновой кислоты в лечении функциональной астении у детей младшего школьного возраста

Исследование эффективности применения гопантеновой кислоты в лечении функциональной астении у детей младшего школьного возраста

Синдром дефицита внимания с гиперактивностью у детей: эффективность фармакотерапии гопантеновой кислотой

Синдром дефицита внимания с гиперактивностью у детей: эффективность фармакотерапии гопантеновой кислотой

Перспективы разработки новой комбинированной лекарственной формы гопантеновой кислоты

Перспективы разработки новой комбинированной лекарственной формы гопантеновой кислоты

Применение препарата гопантеновой кислоты для коррекции когнитивных нарушений в послеоперационном периоде у детей

Применение препарата гопантеновой кислоты для коррекции когнитивных нарушений в послеоперационном периоде у детей

The Neurotropic, Anti-Inflammatory, and Antitumor Properties of the Hopantenic Acid Molecule Based on Chemoinformatic Analysis

Hopantenic acid is a known nootropic agent with a chemical structure close to that of pantothenic acid (vitamin B5). The neurotropic effect of hopantenic acid may occur as a result of binding with δ and κ opioid receptors, modulating acetylcholine secretion, and interacting with dopamine receptors. Apart from the neurotropic effects, hopantenic acid can modulate the metabolism of prostaglandins and steroids, and may have antitumor actions.